E-submission
THE KOREAN LIVER CANCER ASSOCIATION
Articles
- Page Path
- HOME > J Liver Cancer > Volume 12(1); 2012 > Article
- Case Report A Case of Improvement of Hypoglycemia by Sorafenib in Hepatocellular Carcinoma
- Kwang Il Ko1, Young Kul Jung1, Jungsuk An2, Oh Sang Kwon1, Yun Soo Kim1, Duck Joo Choi1, Ju Hyun Kim1
-
Journal of Liver Cancer 2012;12(1):47-50
DOI: https://doi.org/
Published online: February 28, 2012
1Departments of Internal Medicine, Gil Hospital, Gachon University of Medicine and Science, Incheon, Korea
2Departments of Pathology, Gil Hospital, Gachon University of Medicine and Science, Incheon, Korea
2Departments of Pathology, Gil Hospital, Gachon University of Medicine and Science, Incheon, Korea
-
Corresponding author:
Yun Soo Kim,
Email: kimys@gilhosital.com
- 520 Views
- 0 Download
- 0 Crossref
- 0 Scopus
Abstract
The prevalence of hypoglycemia in hepatocellular carcinoma (HCC) ranged from 4 to 27%. The causes of hypoglycemia in HCC are two type. Type A is a poorly differentiated tumor with mild to moderate severity of hypoglycemia that occurs in the late stage of the disease. The less common type B tumor is a well-differentiated slow growing tumor in which severe hypoglycemia occurs in early stages of the disease. We reported a case of improvement of hypoglycemia due to HCC by sorafenib.
Follow JLC on Twitter